With many such obstacles overcome, along with a handful of regulatory approvals granted, ASO- and siRNA-based therapies have received a shot in the arm. Dozens of candidates are now in clinical ...

Over the past decade, short interfering RNA (siRNA) or antisense oligonucleotide (ASO)-based gene knockdown ... molecules—rapidly cleared by the kidney and with minimal if any cellular uptake ...

Ben Hargreaves speaks to Liberate Bio, a company that is hoping to address the delivery issues that could prevent mRNA, as well as siRNA and ASO therapeutics, from reaching their full potential ...